Cargando…
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential gene therapy for a number of human diseases. To date, the safety of AAV vectors in 176 phase I, II, and III clinical tr...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378346/ https://www.ncbi.nlm.nih.gov/pubmed/30815511 http://dx.doi.org/10.1016/j.omtm.2019.01.008 |